Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat Extension Study in Alagille Syndrome
NCT02047318Phase 2Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Dec 2013
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in Alagille syndrome (ALGS), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid Levels. Started Dec 2013; status: completed.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NCT02047318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047318.